NASDAQ: LENZ
LENZ Therapeutics, Inc.
Healthcare · Biotechnology
Market Cap
$192.83M
52w High
$50.40
52w Low
$5.84
P/E
-1.77
Volume
1.12M
Outstanding Shares
31.35M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 79.52% over the last year. Free cash flow declined 67.89% over the trailing twelve months.
What the market seems to be pricing
The market appears to be responding to weaker operating momentum rather than only rerating the stock.
What would invalidate this read
Operating margin stands at -563.83%. Free cash flow fell 67.89% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Company profile
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States.
Valuation
Stock splits
Every 7 shares became 1
Profitability & growth
Analyst consensus
4
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Jul 29, 2026
Q3 FY26 · EPS est -$1.07 · Revenue est $2.49M
View